Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
/ 2 items
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.